University of California Researchers Validate Automated Breast Density Software

Share Article

VolparaDensity Volumetric Breast Density Software from Matakina Correlated to MRI in Independent Research

“UCSF is renowned for its quality medical research and we are delighted that these independent results continue to validate VolparaDensity’s volumetric breast density versus ground truth,” said Ralph Highnam.

RSNA: A study published yesterday by researchers at the University of California San Francisco (UCSF) in PLOS ONE journal, has provided further validation for automated volumetric breast density software. Volumetric density techniques were found to compare well with breast MRI results, with substantial agreement reported.

The value of volumetric breast density was also detailed in a scientific presentation this week at the 99th Annual Meeting of the Radiology Society of North America (RSNA), December 1-6, 2013. “Breast Density: Methods of Assessment, Implications for Clinical Practice and Practice Module” was presented by researchers from Brigham & Women’s Hospital.

In the UCSF study, “Agreement of Mammographic Measures of Volumetric Breast Density to MRI,” researchers compared several automated methods of assessing volumetric breast density from digital screening mammograms and evaluated their agreement with a quantitative volumetric MRI-based technique. The results demonstrated that VolparaDensity had the highest correlation with MRI for fibroglandular volume, outperforming the other commercial methods.

“UCSF is renowned for its quality medical research and we are delighted that these independent results continue to validate VolparaDensity’s volumetric breast density versus ground truth,” said Ralph Highnam, CEO of Matakina International, developers of the VolparaDensity software included in the study. “Recognizing that volumetric measures are key to so many aspects of breast imaging and cancer screening, Matakina continues to invest in and develop volumetric density and analytics tools – the era of quantitative, volumetric breast analysis is here.”

Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images and help evaluate who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool which automatically generates an objective, automatic measurement of volumetric breast density and a FDA cleared BI-RADS breast density category. To date, more than 2 million women have had their volumetric breast density analyzed using VolparaDensity.

For our latest news, please visit http://www.virtualpressoffice.com/kit/kr2c

About Matakina
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Matakina International, Limited is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Volpara’s founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK; Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.

Media Contact:
Chris K. Joseph
510/435-4031
chris(at)ckjcomm(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Mezzoprete
Matakina
+1 (585) 737-0587
Email >
Visit website